Prima BioMed (NASDAQ:IMMP) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Prima BioMed (NASDAQ:IMMP) from a sell rating to a hold rating in a report issued on Saturday morning.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Prima BioMed in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Prima BioMed Price Performance

Shares of Prima BioMed stock opened at $2.64 on Friday. Prima BioMed has a 52 week low of $1.32 and a 52 week high of $3.53. The business has a 50 day moving average price of $2.84 and a 200-day moving average price of $2.16.

Institutional Investors Weigh In On Prima BioMed

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC lifted its holdings in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.32% of the company’s stock.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.